SLN

#3393
Silence Therapeutics Plc American Depository Share
6.12 USD
+1.83%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
6.12
6.12
Range Annuel
2.63
7.91
Changement quotidien
+1.83%
Changement Mensuel
-18.40%
Evolution sur 6 mois
+3.90%
Changement Annuel
+119.35%
Clôture Précédente
6.01
Open
6.12
Bid
Ask
Low
6.12
High
6.12
Volume
41
Open full chart

Financials

Overview Relevé Statistics
Quarterly Annual
  • Market Capitalization 289.07 M
  • Employee 88
  • Founded 1994
  • CEO Craig A Tooman
  • Website www.silence-therapeutics.com
  • Headquarter United Kingdom
  • FIGI BBG00WVTHPN2
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-9.65
Price to sales ratio
1 541.15

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics is a London-based pharmaceutical company formed in 1994. The company has pioneered the development of short-interfering ribonucleic acid therapeutics for the treatment of rare diseases. Silence Therapeutics has offices in London, New Jersey, and Berlin, with its corporate headquarters located in Hammersmith, London.

Nouvelles